"RP-HPLC Method for Simultaneous Quantification of Vilanterol and Fluticasone Furoate: Development and Validation"
Keywords:
HPLC, Fluticasone, Vilanterol, Pharmaceutical, Spectrometer, ChromatographyAbstract
This study aimed to develop and validate an RP-HPLC method for quantifying Vilanterol and Fluticasone Furoate in pharmaceutical formulations used for respiratory disorders. The method utilized an Agilent Poroshell EC-120 C18 column with a mobile phase of 0.1% Perchloric acid and Acetonitrile (35:65). Key parameters like wavelength, column temperature, flow rate, and injection volume were optimized. Method validation followed ICH guidelines, ensuring specificity, linearity (R² = 1 over ranges of 4-6 µg/ml for Vilanterol and 16-24 µg/ml for Fluticasone Furoate), LOD (0.03 µg/ml for Vilanterol, 0.02 µg/ml for Fluticasone Furoate), LOQ (0.09 µg/ml for Vilanterol, 0.07 µg/ml for Fluticasone Furoate), precision, accuracy, and robustness. Results confirmed the method's efficiency and suitability for simultaneous drug determination in formulations.
References
Nash R.A. and Watcher A.H. Pharmaceutical process validation. CBS publishers and Distributors, New Delhi.
E. Rutkowska, K. Pajak and K. Jozwiak, Acta. Pol. Pharm. Drug. Res., 70 (2013) 3-18.
Avdeef, K. J. Box, J. E. A Comer, M. Gilges , M. Hadley, C. Hibbert , W. Patterson, K.Y. Tam, J. Pharm. Biomed. Anal. 20 (1999) 631–641.
A.M. Sameer, K. AbdulrahmanBasavaiah, 2011. Chem. Ind. Chem. Eng. Q. 17 (2011) 173–178.
N. Matei, S. Birghila, V. Popescu, S. Dobrinas, A. Soceanu, C. Oprea, V. Magearu, Rom. J. Phys. 53 (2008) 343–351.
Ettre, C. (2001). "Milestones in Chromatography: The Birth of Partition Chromatography" (PDF). LCGC. 19 (5): 506–512. Retrieved 2016-02-26.
Martin, A J P; Synge, R L M (1941). "Separation of the higher monoamino-acids by counter-current liquid-liquid extraction: the amino-acid composition of wool". Biochemical Journal. 35 (1–2): 91–121.
FDA Approved Drug Products: Arnuity Ellipta (fluticasone furoate) powder for inhalation.
DailyMed: Flonase Sensimist (fluticasone furoate) nasal spray
FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation.
FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation (December 2022)
FDA Approved Drug Products: Breo Ellipta (fluticasone furoate/vilanterol) powder for inhalation (May 2023)
Fluticasone Furoate MSDS
Fluticasone furoate/vilanterol: Clinical Pharmacology and Biopharmaceutics review
Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun
Harrell AW, Siederer SK, Bal J, Patel NH, Young GC, Felgate CC, Pearce SJ, Roberts AD, Beaumont C, Emmons AJ, Pereira AI, Kempsford RD: Metabolism and disposition of vilanterol, a long-acting beta(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89-100. doi: 10.1124/dmd.112.048603. Epub 2012 Oct 4.
Spyratos D, Sichletidis L: Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review. Ther Clin Risk Manag. 2015 Mar 25;11:481-7. doi: 10.2147/TCRM.S67491. eCollection 2015.
Malerba M, Radaeli A, Montuschi P, Morjaria JB: Vilanterol trifenatate for the treatment of COPD. Expert Rev Respir Med. 2016 Jul;10(7):719-31. doi: 10.1080/17476348.2016.1184976. Epub 2016 May 25.
Kempsford R, Norris V, Siederer S: Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8.
FDA Approved Drug Products: ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) for oral inhalation use.
FDA Approved Drug Products: Breo Ellipta (fluticasone furoate/vilanterol) powder for inhalation (May 2023)
Health Canada Approved Drug Proucts: BREO ELLIPTA (fluticasone furoate/vilantero) dry powder for oral inhalation
Displacement Chromatography. Sacheminc.com. Retrieved 2011-06-07.
Patel, D., Namdev, K. K., Verma, K., Gururani, R., Tiwari, A., Kumar, P., Dewangan, R. P., Wabaidur, S. M., Sharma, S., & Dwivedi, J. (2019). HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1132, 121842. https://doi.org/10.1016/j.jchromb.2019.121842
Yadav, S., Jain, V., Magar, H., Kumar, M. V., Warde, S., & Singh, R. M. (2023). A Novel RP-HPLC Method for Simultaneous Estimation of Vilanterol Trifenatate, Umeclidinium Bromide and Fluticasone Furoate in Inhalation Dry Powder Formulation. Journal of chromatographic science, bmad075. Advance online publication. https://doi.org/10.1093/chromsci/bmad075
S.K. Masimukku and R. Chintala. Development and validation of stability indicating RP-HPLC method for fluticasone furoate and vilanterol in pharmaceutical formulations. Indian Drugs. 2018, 55(3):27-31. DOI:10.53879/id.55.03.10849.
Kumari, Y A S J Prasanna & Kumari, P Rajani. Sensitive and stable RP-HPLC method development and validation for the simultaneous analysis of Vilanterol trifenatate and Fluticasone Furoate in pharmaceutical formulations. Journal of Atoms and Molecules. 2018, Vol. 8, Iss. 3, 1166-1174.
Ravalika, Dr. Vallikumari, and Dr. B. Raj Kamal. Analytical Method Development and Validation for the Simultaneous Estimation of Fluticasone and Vilanterol by RPHPLC. Journal of Global Trends in Pharmaceutical Sciences. 2021; 12(3): 9787 – 9799.
Sunil Kumar Chaitanya Padavala et al. HPLC Method Development and Validation for the Estimation of Umeclidinium and Vilanterol in Bulk Dosage Forms. Ijppr. Human, 2023; Vol. 27 (3): 42-56.
Masimukku, S. K., & Chintal, R. (2017). Development and validation of spectrophotometric methods for simultaneous estimation of vilanterol and fluticasone furoate in pharmaceutical formulations. Asian Journal of Pharmaceutical and Clinical Research, 10(4), 302–305. https://doi.org/10.22159/ajpcr.2017.v10i4.16748
Swapna, P. Sowjanya, Dr. Gampa Vijaya Kumar. Analytical Method Development and Validation for the Simultaneous Estimation of Fluticasone and Vilanterol by RP-HPLC Method in its Pharmaceutical Dosage Forms. Pharma Reseach Library, 2024.
G. Raveendra Babu, M. Sowjanya, M. Ramayyappa, Md. Abdul Karishma, V. Bharathi, G. Renuka Swathi, Ch. Renuka, G. Gopala Krishna, M. Lavanya. Rapid RP-HPLC Method for Simultaneous estimation of Umeclidinium and Vilanterol in human plasma. Research Journal of Pharmacy and Technology 2023; 16(3):1017-2. doi: 10.52711/0974-360X.2023.00170.
Blais, C. M., Ducharme, F. M., & Lemière, C. (2014). Safety and efficacy of long-acting β2-agonists in the treatment of asthma. Therapeutic Advances in Respiratory Disease, 8(4), 145-159.
Dong, M. W. (2006). Modern HPLC for Practicing Scientists. John Wiley & Sons.
ICH Q2(R1). (2005). Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonisation.
Lipworth, B. J. (2014). Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Archives of Internal Medicine, 159(9), 941-955.
Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2012). Introduction to Modern Liquid Chromatography. John Wiley & Sons.